Your browser is no longer supported. Please, upgrade your browser.
Settings
BOLD Audentes Therapeutics, Inc. daily Stock Chart
BOLD [NASD]
Audentes Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.98 Insider Own1.10% Shs Outstand45.76M Perf Week0.25%
Market Cap2.72B Forward P/E- EPS next Y-4.21 Insider Trans-11.66% Shs Float42.30M Perf Month119.19%
Income-175.50M PEG- EPS next Q-1.03 Inst Own- Short Float4.93% Perf Quarter85.45%
Sales- P/S- EPS this Y-28.00% Inst Trans0.47% Short Ratio1.98 Perf Half Y49.06%
Book/sh8.42 P/B7.05 EPS next Y-1.20% ROA-38.00% Target Price58.75 Perf Year158.94%
Cash/sh7.68 P/C7.73 EPS next 5Y13.20% ROE-42.60% 52W Range17.95 - 59.68 Perf YTD178.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-0.47% Beta1.75
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin- 52W Low230.92% ATR1.91
Employees207 Current Ratio12.80 Sales Q/Q- Oper. Margin- RSI (14)90.62 Volatility0.38% 2.25%
OptionableYes Debt/Eq0.00 EPS Q/Q-3.40% Profit Margin- Rel Volume0.79 Prev Close59.37
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume1.06M Price59.40
Recom2.90 SMA2046.93% SMA5081.92% SMA20068.47% Volume834,652 Change0.05%
Dec-06-19Downgrade JP Morgan Overweight → Neutral
Dec-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Dec-04-19Downgrade Chardan Capital Markets Buy → Neutral
Dec-03-19Upgrade Robert W. Baird Underperform → Neutral
Dec-03-19Upgrade Citigroup Sell → Neutral
Dec-03-19Downgrade Wedbush Outperform → Neutral
Dec-03-19Downgrade Raymond James Outperform → Mkt Perform
Dec-03-19Downgrade Piper Jaffray Overweight → Neutral
Dec-03-19Downgrade Mizuho Buy → Neutral
Dec-03-19Downgrade H.C. Wainwright Buy → Neutral
Dec-03-19Downgrade Guggenheim Buy → Neutral
Dec-03-19Downgrade BMO Capital Markets Outperform → Market Perform
Nov-19-19Upgrade Evercore ISI In-line → Outperform $40
Oct-03-19Initiated Robert W. Baird Underperform $10
Apr-26-19Reiterated H.C. Wainwright Buy $44 → $48
Apr-26-19Downgrade Citigroup Neutral → Sell $28 → $32
Feb-25-19Upgrade Chardan Capital Markets Neutral → Buy $35 → $40
Jan-11-19Upgrade Guggenheim Neutral → Buy
Nov-26-18Initiated JP Morgan Overweight $35
Nov-07-18Reiterated B. Riley FBR Sell $20 → $21
Dec-13-19 04:15PM  URGENT NEWS: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Merger ACCESSWIRE
12:10PM  MERGER ALERT - BOLD and TCBI: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies ACCESSWIRE
08:55AM  Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up Zacks
Dec-11-19 03:00PM  SHAREHOLDER ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Merger ACCESSWIRE
Dec-10-19 09:30PM  BOLD, MDCO, AYR, and PEGI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
06:40PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Audentes Therapeutics, Inc. - (NasdaqGS: BOLD) ACCESSWIRE
04:35PM  STOCKHOLDER ALERT: Monteverde & Associates PC Continues its Legal Inquiry for the Recent Acquisition ACCESSWIRE
11:51AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders INST, AKS, BOLD, SORL GlobeNewswire
Dec-09-19 01:45PM  MERGER ALERT - BOLD and INST: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies ACCESSWIRE
Dec-06-19 08:03PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Audentes Therapeutics, Inc. - BOLD PR Newswire
11:33AM  Hedge Funds Are Souring On Audentes Therapeutics, Inc. (BOLD) Insider Monkey
02:12AM  Astellas Pharma Inc. -- Moody's reviews Astellas Pharma's A1 ratings for downgrade Moody's
Dec-05-19 04:32PM  Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
09:37AM  4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
Dec-04-19 10:15AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Audentes Therapeutics, Inc. to Astellas Pharma Inc. is Fair to Shareholders ACCESSWIRE
09:30AM  Company News for Dec 4, 2019 Zacks
07:06AM  The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 07:13PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc. PR Newswire +105.98%
04:22PM  This Gene Therapy Stock Just Netted A $3 Billion Bid Who's Next? Investor's Business Daily
12:37PM  Gene Therapy M&A Appetite Provides Lift After Audentes Deal Bloomberg
11:53AM  The Gene Therapy Names Moving On The Audentes Buyout Deal Benzinga
11:35AM  AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm PR Newswire
11:11AM  Astellas $3 billion gene therapy deal steadies investors after stalled Roche acquisition MarketWatch
11:03AM  Gene Therapies Get a $3 Billion Vote of Confidence Bloomberg
10:49AM  Japan's Astellas To Buy Gene Therapy Company Audentes For $3B Cash Benzinga
09:37AM  Breakthrough gene therapy company snared by Japanese biopharma for $3 billion American City Business Journals
09:31AM  Gene-Therapy Firm Audentes Sells for Double Its Share Price. It Could Be the First of Many More Deals. Barrons.com
09:15AM  AUDENTES THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout ACCESSWIRE
08:26AM  Astellas bets $3 billion in gene therapy deal MarketWatch
07:59AM  The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
06:09AM  [video]Audentes Therapeutics Soars on Astellas Pharma's $3 Billion Purchase TheStreet.com
Dec-02-19 11:10PM  Audentes Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Audentes Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm BOLD GlobeNewswire
06:01PM  Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics Business Wire
Nov-26-19 04:01PM  Audentes Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Nov-21-19 04:54AM  Edited Transcript of BOLD earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-19 04:01PM  Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Oct-31-19 07:00AM  Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019 Business Wire
Oct-25-19 10:01AM  Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD) Insider Monkey
Oct-05-19 07:01AM  Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society Business Wire
Oct-04-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
01:30AM  Edited Transcript of BOLD earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-01-19 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences Business Wire -6.19%
Sep-30-19 08:00AM  Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM) Business Wire
Sep-19-19 09:59AM  Have Insiders Been Selling Audentes Therapeutics, Inc. (NASDAQ:BOLD) Shares? Simply Wall St. +5.31%
Sep-06-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-26-19 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Aug-20-19 12:02PM  Parents Push One Rare-Disease Drug Through FDA, Not Its Successor Bloomberg
10:03AM  Sarepta Stock Falls as FDA Denies Approval to Golodirsen Zacks
Aug-19-19 08:58AM  Solid Biosciences Surges on DMD Gene Therapy Study Amendments Zacks
Aug-06-19 11:24PM  Audentes Therapeutics, Inc. (BOLD) Q2 2019 Earnings Call Transcript Motley Fool
04:01PM  Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update PR Newswire
Aug-01-19 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Jul-30-19 08:00AM  Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019 PR Newswire
Jul-19-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jul-09-19 09:56AM  How Does Investing In Audentes Therapeutics, Inc. (NASDAQ:BOLD) Impact The Volatility Of Your Portfolio? Simply Wall St.
Jun-19-19 10:41AM  Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD) Insider Monkey
Jun-07-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +6.68%
May-29-19 04:01PM  Audentes Therapeutics Announces Changes to Senior Management Team PR Newswire
May-15-19 04:45AM  Edited Transcript of BOLD earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 09:23AM  Audentes Therapeutics, Inc. (BOLD) Q1 2019 Earnings Call Transcript Motley Fool
08:00AM  Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference PR Newswire
May-07-19 04:32PM  Audentes Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update PR Newswire
May-02-19 01:53PM  Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD) Insider Monkey
May-01-19 02:15PM  Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy PR Newswire
Apr-30-19 08:00AM  Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019 PR Newswire
Apr-26-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Apr-23-19 08:00AM  Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility PR Newswire
Apr-22-19 02:39PM  Estimating The Fair Value Of Audentes Therapeutics, Inc. (NASDAQ:BOLD) Simply Wall St.
Apr-15-19 04:01PM  Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy PR Newswire
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
07:00AM  Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy PR Newswire
Apr-05-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Apr-01-19 08:00AM  Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer PR Newswire
Mar-29-19 07:25AM  Factors of Influence in 2019, Key Indicators and Opportunity within Nutanix, Steel Dynamics, Audentes Therapeutics, Comfort Systems, LHC Group, and Cambrex New Research Emphasizes Economic Growth GlobeNewswire
Mar-18-19 04:20PM  Spark Unlikely To Get A Better Bid But These Stocks Could Be In Play Investor's Business Daily
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
Mar-08-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
11:27AM  Introducing Audentes Therapeutics (NASDAQ:BOLD), The Stock That Dropped 10% In The Last Year Simply Wall St.
Mar-07-19 09:07AM  Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know Zacks
Mar-03-19 10:28PM  Edited Transcript of BOLD earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-02-19 01:48PM  Audentes Therapeutics Inc (BOLD) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-28-19 08:00AM  Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases PR Newswire +10.26%
Feb-27-19 09:24PM  Audentes Therapeutics, Inc. (BOLD) Q4 2018 Earnings Conference Call Transcript Motley Fool -6.28%
04:01PM  Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update PR Newswire
Feb-26-19 11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks
Feb-21-19 08:00AM  Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019 PR Newswire
Feb-20-19 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Feb-13-19 08:20AM  Report: Developing Opportunities within Dunkin' Brands Group, Murphy Oil, NII, Audentes Therapeutics, RealNetworks, and MDC Partners Future Expectations, Projections Moving into 2019 GlobeNewswire
Feb-08-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Feb-05-19 02:25PM  Mizuho's 9 Best Biotech Stocks to Buy for 2019 Kiplinger
Jan-31-19 08:00AM  Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation PR Newswire
Jan-07-19 08:00AM  Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities PR Newswire +6.63%
Jan-04-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jan-03-19 08:00AM  Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer PR Newswire
Jan-02-19 08:00AM  Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-21-18 10:11AM  Need To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling Shares Simply Wall St.
Dec-18-18 01:33AM  Is Audentes Therapeutics, Inc. (BOLD) Going to Burn These Hedge Funds? Insider Monkey -5.70%
Dec-13-18 05:18PM  Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay American City Business Journals
Dec-07-18 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patterson Matthew RChief Executive OfficerNov 08Option Exercise9.5014,426137,047127,820Nov 12 05:32 PM
Patterson Matthew RChief Executive OfficerNov 08Sale30.0014,426432,780113,394Nov 12 05:32 PM
LANGE LOUIS GDirectorSep 23Sale32.181,00032,18214,678Sep 25 06:11 PM
LANGE LOUIS GDirectorSep 23Sale32.1610,000321,616275,799Sep 25 06:11 PM
Patterson Matthew RChief Executive OfficerAug 12Option Exercise9.5020,000190,000135,368Aug 14 07:03 PM
Patterson Matthew RChief Executive OfficerAug 12Sale34.0420,000680,835115,368Aug 14 07:03 PM
LANGE LOUIS GDirectorJun 24Sale38.201,00038,20115,678Jun 26 04:07 PM
LANGE LOUIS GDirectorJun 24Sale37.7720,000755,413285,799Jun 26 04:07 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMay 13Option Exercise0.7910,0007,90028,236May 15 04:42 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMay 13Sale36.9810,000369,79818,236May 15 04:42 PM
LANGE LOUIS GDirectorMar 25Sale35.981,55856,0580Mar 27 05:03 PM
LANGE LOUIS GDirectorMar 25Sale36.0020,000720,015305,799Mar 27 05:03 PM
Patterson Matthew RChief Executive OfficerFeb 25Option Exercise1.0521,00022,020135,700Feb 27 04:31 PM
PRASAD SUYASHSenior VP & Chief Med OfficerFeb 25Option Exercise0.7910,0007,90028,236Feb 27 04:32 PM
Patterson Matthew RChief Executive OfficerFeb 25Sale30.0021,000630,000118,700Feb 27 04:31 PM
PRASAD SUYASHSenior VP & Chief Med OfficerFeb 25Sale30.0610,000300,55318,236Feb 27 04:32 PM
Holles Natalie C.President and COOJan 24Option Exercise2.768,30022,94933,390Jan 25 07:28 PM
LANGE LOUIS GDirectorDec 24Sale18.5312,000222,365558Dec 27 05:43 PM
LANGE LOUIS GDirectorDec 24Sale18.6720,000373,434325,799Dec 27 05:43 PM